Kiran Vyapar Ltd
KIRANVYPARKiran Vyapar Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is already 5 weeks into its uptrend — timing risk, not thesis risk.
The price is in a confirmed uptrend (5 weeks in) while the P/BV sits at the 32nd percentile of its own 10-year range. Underneath, the last four quarters read mixed — profit +0.0% year on year, with the the net margin at 57.6%. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Kiran Vyapar Ltd trades at ₹198, in a confirmed uptrend and 5 weeks into that stage. That is +0.7% against its own 200-day average. It sits at 78% of a 52-week range of ₹163 to ₹208. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 5 straight weeks.
Today the stock is in a confirmed uptrend — week 5 of stage 2, confirmed. At ₹198 it trades +0.7% versus its 200-day average and sits at 78% of its 52-week range (₹163–₹208).
Against the market, two honest reads. Cumulative: over the last 5 months the stock moved +2% while the NIFTY 500 moved −2% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 5 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation For a bank we price the book, not the earnings: P/BV is what the market pays for each ₹1 of the bank's net worth. A bank below 1× book is priced below the value of what it owns, net of what it owes.
Kiran Vyapar Ltd trades at 0.3× P/BV, near the bottom of its own range — cheaper only 32% of the time. Its long-run median P/BV is 0.3×, measured across 10.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/BV of 0.3× is near the bottom of its own range — cheaper only 32% of the time, against a long-run median of 0.3× measured over 10.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
The honest context for that discount: a bank earning about 0% on its equity is worth less per rupee of book, and the market has priced that in rather than overlooked it. The discount closes only if the returns themselves improve.
Put together: the multiple is low against its own past, so the story rests on the book-value line underneath it, not the multiple.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Kiran Vyapar Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −100.0% at the trough to +0.0% off a 2-quarter-old trough (single-quarter readings), ROE slipping at 0.0%. The read is built from 10 quarters across 3 curves, on partial evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −5.3% | +16.9% | −5.4% | +3.5% |
| Profit | −98.3% | −70.5% | −60.0% | −30.7% |
| EPS | −98.3% | −70.4% | −59.9% | −30.2% |
4-Factor Sector Score
33.0/100 — rank 20 of 24 in Finance & Investments - Others · 64% evidence confidence
Kiran Vyapar Ltd scores 33.0 out of 100 against the 24 companies it is compared with in Finance & Investments - Others, ranking 20. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 10.2 + 7.5 + 3.4 + 11.9 = 33. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if ROA rolls over or gross NPA rises while sector-relative strength deteriorates.
Revenue For a bank, revenue is everything the franchise earns — interest on the loan book plus fee and other income.
Kiran Vyapar Ltd reported ₹33.0 Cr of income in the Jun 26 quarter, +22.2% year on year. Over 10 years it has compounded at 3.5% a year. The last full year, FY26, came in at ₹107 Cr. The last four reported quarters add to ₹112 Cr.
FY26 revenue came in at ₹107 Cr (−5.3% on the year), capping 10 years at 3.5% compound. The latest quarter (Jun 26) printed ₹33.0 Cr, +22.2% year on year.
Pace check: the last four quarters averaged +1.8% growth against the decade's 3.5% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +0.9% over the last 4 quarters against +9.7%/yr over the last 8 — rolling over; TTM profit −86.7% vs −68.6%/yr — rolling over.
Net margin Net margin — what the bank keeps of every ₹100 of revenue after every cost, provision and tax. It is the cleanest single margin we can read for a lender.
Kiran Vyapar Ltd's net margin is 57.6% in the Jun 26 quarter, −12.8 percentage points against the same quarter a year ago. Across 12 fiscal years the net margin has ranged −13.3% to 89.3%. The current quarter sits inside that band.
The latest quarter's net margin is 57.6%, −12.8 pp against the same quarter a year ago. Across 12 fiscal years the net margin has ranged −13.3%–89.3%.
Why: the numbers show the net margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Kiran Vyapar Ltd earned ₹19.0 Cr of net profit in the Jun 26 quarter, +0.0% year on year. Full-year FY26 profit was ₹1.0 Cr. The 10-year compound rate is −30.7%. That is 57.6% of the quarter's revenue. The same quarter a year earlier earned ₹19.0 Cr. 3 of the last 12 reported quarters were loss-making.
Jun 26 profit was ₹19.0 Cr, +0.0% year on year. On the full year, FY26 printed ₹1.0 Cr (−98.3%), and the 10-year compound rate is −30.7%.
🚨 Why profit moved: revenue contributed +22.2% and the margin −12.8 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −79.2% vs revenue +1.8%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Asset quality — the ladder Gross NPA is the slice of the loan book where repayments have stopped. Net NPA is what remains after the money already set aside against those loans. Falling is healing; rising is damage arriving.
Loan-book quality history is not available for Kiran Vyapar Ltd, so this section names the gap rather than estimating a ratio. No gross or net non-performing-asset series is filed in a form this page can read, and none is inferred from the profit line. The income, margin and return sections above carry the evidence this business does report.
We do not hold quarterly loan-book quality numbers for this bank, so this section states that plainly rather than working around it.
Why: loan-book quality is the engine room of a bank, and its drivers — slippages, recoveries, provisioning — sit below what we hold for this name; the sections around it carry the reads we can stand behind.
The loan book We read the loan book through revenue — when the book grows, revenue grows with it. It is a rough proxy, and we say so: rate moves and fee swings can shift it a few points in any one year.
Kiran Vyapar Ltd's revenue grew −5.3% in FY26 to ₹107 Cr, so the book is flat. The latest quarter ran +22.2% year on year. The net margin on that income is 57.6%, −12.8 percentage points against a year ago. Interest income is a proxy for the book; rate moves can shift it a few points in any one year.
FY26 revenue was ₹107 Cr, −5.3% on the year, and the latest quarter ran +22.2% year on year. The net margin on that revenue is 57.6% this quarter (−12.8 pp YoY) — growth with a narrowing margin on it.
The synthesis: a lender compounds when the book grows while the margin holds and the loan book stays clean — gross NPA is the loan-quality read we carry here.
Returns on equity and assets Two numbers rate a bank: ROE — what it earns on shareholder money — and ROA — what it earns on everything it deploys. ROE above ~13–15% earns its keep; below that, growth builds book slowly.
Kiran Vyapar Ltd earns a return on equity of 0% in FY26. Its trough over the ladder below was −1% in FY20. On the asset side every ₹100 of the balance sheet earned about ₹1.14, which is the return before leverage is applied.
FY26 ROE came in at 0%, recovered from a FY20 trough of −1%. On assets, the latest reading is about 1.14% — every ₹100 the bank deploys earns roughly ₹1.14 a year. That return is below the bar a bank must clear to compound book value quickly — which is also the honest reason the stock trades where it does.
Why ROE moved: profit compounded −30.7% a year over 10 years while the equity base grew more slowly — earnings recovering faster than book value builds is what lifts ROE off a trough.
Debt
For a bank, borrowings are raw material, not a warning sign — solvency is read through the returns and the loan book. A manufacturer’s debt is a claim against its profits, so the debt-to-equity lens that works everywhere else misleads on a lender and is not applied here.
A manufacturer’s debt is a claim against its profits; a bank’s borrowings are its inventory — money taken in to be lent out. The debt lens that works everywhere else misleads here, so this page does not apply it. The solvency questions for a bank — is the loan book sound, is the equity earning — are read through the loan-book and returns sections above.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Kiran Vyapar Ltd moved a full percentage point over the last two years — the register is quiet. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: +0.0 points over 8 quarters to 75.0%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Kiran Vyapar Ltd: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre. The Z-score was built for manufacturers and is not applied to banks and lenders, so solvency here is read from the capital and asset-quality lines instead.
The safety line in one sentence: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Abans Financial Services LtdAFSL | 72.7/100Favorable setup80% evidence | TURNING | 25.8/35 Income 100% · PAT 17.9% 81% evidence | 15.1/25 ROA 3.6% · ROE 8.3% · GNPA — 68% evidence | 16.0/20 P/BV 0.81× · P/BV÷ROE 0.1 100% evidence | 15.8/20 RS sector 23.9% · RS bench 1.6% · 1Y -5.3%0 of 11 weeks ahead 70% evidence |
| Exact sum: 25.8 + 15.1 + 16 + 15.8 = 72.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2CSL Finance LtdCSLFINANCE | 63.3/100Mixed-positive evidence90% evidence | BASING | 22.1/35 Income 19.7% · PAT 14.7% 76% evidence | 23.0/25 ROA 9% · ROE 14.9% · GNPA 0.9% 95% evidence | 11.9/20 P/BV 0.79× · P/BV÷ROE 0.05 100% evidence | 6.3/20 RS sector -9.8% · RS bench -12.3% · 1Y -28.2%1 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 23 + 11.9 + 6.3 = 63.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3BF Investment LtdBFINVEST | 62.8/100Mixed-positive evidence86% evidence | ASLEEP | 28.5/35 Income 22.2% · PAT 100% 81% evidence | 11.9/25 ROA 3% · ROE 3.6% · GNPA — 68% evidence | 8.0/20 P/BV 0.19× · P/BV÷ROE 0.05 100% evidence | 14.4/20 RS sector 8.1% · RS bench 5.5% · 1Y -5.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 28.5 + 11.9 + 8 + 14.4 = 62.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Master Trust LtdMASTERTR | 56.9/100Mixed-positive evidence80% evidence | TURNING | 13.9/35 Income 7% · PAT 8.1% 81% evidence | 19.2/25 ROA 5.6% · ROE 17.3% · GNPA — 68% evidence | 14.5/20 P/BV 1.28× · P/BV÷ROE 0.07 70% evidence | 9.3/20 RS sector -5.9% · RS bench -9.1% · 1Y -40.7%7 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 19.2 + 14.5 + 9.3 = 56.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 5Balmer Lawrie Investment LtdBLIL | 54.2/100Mixed-positive evidence86% evidence | ASLEEP | 15.4/35 Income 8.8% · PAT 4.1% 81% evidence | 18.8/25 ROA 7.9% · ROE 12.7% · GNPA — 68% evidence | 12.7/20 P/BV 1.03× · P/BV÷ROE 0.08 100% evidence | 7.3/20 RS sector -3.5% · RS bench -5.8% · 1Y -19%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.4 + 18.8 + 12.7 + 7.3 = 54.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Dolat Algotech LtdDOLATALGO | 53.9/100Mixed-positive evidence80% evidence | ASLEEP | 8.6/35 Income -11.6% · PAT -21.2% 81% evidence | 18.8/25 ROA 8.5% · ROE 12.1% · GNPA — 68% evidence | 16.4/20 P/BV 1.05× · P/BV÷ROE 0.09 100% evidence | 10.1/20 RS sector 1.6% · RS bench -9% · 1Y -21.6%0 of 11 weeks ahead 70% evidence |
| Exact sum: 8.6 + 18.8 + 16.4 + 10.1 = 53.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 7Bengal & Assam Company LtdBENGALASM | 52.7/100Mixed-positive evidence64% evidence | 17.4/35 Income 12.1% · PAT 3.4% 62% evidence | 13.1/25 ROA — · ROE 8.1% · GNPA — 34% evidence | 15.2/20 P/BV 0.65× · P/BV÷ROE 0.08 100% evidence | 7.0/20 RS sector -7.4% · RS bench -3.8% · 1Y -30.5%1 of 8 weeks ahead 70% evidence | |
| Exact sum: 17.4 + 13.1 + 15.2 + 7 = 52.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8PTC India Financial Services LtdPFS | 51.7/100Mixed-positive evidence80% evidence | BASING | 13.1/35 Income -22.7% · PAT -27.8% 81% evidence | 17.4/25 ROA 6.5% · ROE 11% · GNPA — 68% evidence | 15.2/20 P/BV 0.55× · P/BV÷ROE 0.05 100% evidence | 6.0/20 RS sector -4.8% · RS bench -13.2% · 1Y -31.6%0 of 11 weeks ahead 70% evidence |
| Exact sum: 13.1 + 17.4 + 15.2 + 6 = 51.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 9PTL Enterprises LtdPTL | 48.3/100Mixed-negative evidence75% evidence | ASLEEP | 17.1/35 Income 0% · PAT 13.5% 52% evidence | 14.0/25 ROA 3.3% · ROE 5.5% · GNPA — 68% evidence | 8.0/20 P/BV 0.6× · P/BV÷ROE 0.11 100% evidence | 9.2/20 RS sector 1.6% · RS bench -0.7% · 1Y -4.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 14 + 8 + 9.2 = 48.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Industrial & Prudential Investment Company LtdINDPRUD | 47.5/100Mixed-negative evidence80% evidence | ASLEEP | 13.1/35 Income -40% · PAT -3.2% 81% evidence | 16.1/25 ROA 7.3% · ROE 7.7% · GNPA — 68% evidence | 6.0/20 P/BV 1.22× · P/BV÷ROE 0.16 100% evidence | 12.3/20 RS sector -1.4% · RS bench 4.9% · 1Y -7.6%0 of 11 weeks ahead 70% evidence |
| Exact sum: 13.1 + 16.1 + 6 + 12.3 = 47.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11VLS Finance LtdVLSFINANCE | 46.4/100Mixed-negative evidence80% evidence | ASLEEP | 19.3/35 Income -8.4% · PAT 91.7% 81% evidence | 7.8/25 ROA 1% · ROE 0.9% · GNPA — 68% evidence | 4.8/20 P/BV 0.36× · P/BV÷ROE 0.38 100% evidence | 14.5/20 RS sector 12% · RS bench -1.9% · 1Y 4.8%3 of 11 weeks ahead 70% evidence |
| Exact sum: 19.3 + 7.8 + 4.8 + 14.5 = 46.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Prime Securities LtdPRIMESECU | 42.7/100Mixed-negative evidence86% evidence | TURNING | 9.1/35 Income 14.4% · PAT -80% 81% evidence | 13.6/25 ROA 4.6% · ROE 4.1% · GNPA — 68% evidence | 3.2/20 P/BV 3.99× · P/BV÷ROE 0.98 100% evidence | 16.8/20 RS sector 11.4% · RS bench 8.9% · 1Y 17.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 9.1 + 13.6 + 3.2 + 16.8 = 42.7 · Decision use: Price leads the evidence: RS versus the benchmark is 8.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 13NBI Industrial Finance Company LtdNBIFIN | 42.7/100Mixed-negative evidence69% evidence | BREAKING OUT | 20.9/35 Income 55.5% · PAT 65.2% 33% evidence | 6.2/25 ROA 0.3% · ROE 0.4% · GNPA — 68% evidence | 4.6/20 P/BV 0.22× · P/BV÷ROE 0.52 100% evidence | 11.0/20 RS sector -3.1% · RS bench -5.8% · 1Y -24.5%4 of 12 weeks ahead 100% evidence |
| Exact sum: 20.9 + 6.2 + 4.6 + 11 = 42.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Grand Oak Canyons Distillery LtdGRANDOAK | 41.7/100Mixed-negative evidence71% evidence | ASLEEP | 24.3/35 Income 100% · PAT 100% 54% evidence | 3.7/25 ROA 0.1% · ROE 0% · GNPA — 72% evidence | 0.5/20 P/BV 2.12× · P/BV÷ROE 212 100% evidence | 13.2/20 RS sector 4.2% · RS bench -3% · 1Y -10.7%9 of 11 weeks ahead 70% evidence |
| Exact sum: 24.3 + 3.7 + 0.5 + 13.2 = 41.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15The Investment Trust of India LtdTHEINVEST | 39.4/100Mixed-negative evidence75% evidence | BASING | 12.0/35 Income -22.4% · PAT -13.9% 52% evidence | 11.8/25 ROA 2.7% · ROE 4% · GNPA — 68% evidence | 8.0/20 P/BV 0.67× · P/BV÷ROE 0.17 100% evidence | 7.6/20 RS sector -7.7% · RS bench -10.4% · 1Y -38.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12 + 11.8 + 8 + 7.6 = 39.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16PNB Gilts LtdPNBGILTS | 39.2/100Mixed-negative evidence80% evidence | ASLEEP | 8.9/35 Income -5.3% · PAT -69.7% 81% evidence | 10.2/25 ROA 0.7% · ROE 11% · GNPA — 68% evidence | 14.5/20 P/BV 0.79× · P/BV÷ROE 0.07 100% evidence | 5.6/20 RS sector -11.3% · RS bench -6% · 1Y -28.1%4 of 11 weeks ahead 70% evidence |
| Exact sum: 8.9 + 10.2 + 14.5 + 5.6 = 39.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 17Capital India Finance LtdCIFL | 39.2/100Thin evidence · provisional57% evidence | BASING | 17.9/35 Income -1.5% · PAT 100% 52% evidence | 8.5/25 ROA 1.7% · ROE -8.6% · GNPA — 68% evidence | 8.8/20 P/BV 1.28× · P/BV÷ROE — 40% evidence | 4.0/20 RS sector -15.3% · RS bench -20.4% · 1Y -42.3%0 of 11 weeks ahead 70% evidence |
| Exact sum: 17.9 + 8.5 + 8.8 + 4 = 39.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18Crest Ventures LtdCREST | 38.4/100Mixed-negative evidence86% evidence | ASLEEP | 7.3/35 Income -33.2% · PAT -49.3% 81% evidence | 12.0/25 ROA 2.5% · ROE 3.8% · GNPA — 68% evidence | 7.6/20 P/BV 0.79× · P/BV÷ROE 0.21 100% evidence | 11.5/20 RS sector 4% · RS bench 1.5% · 1Y -4.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 7.3 + 12 + 7.6 + 11.5 = 38.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Nalwa Sons Investments LtdNSIL | 38.1/100Mixed-negative evidence76% evidence | TURNING | 20.2/35 Income -20.3% · PAT 37.2% 86% evidence | 5.8/25 ROA 0.3% · ROE 0.3% · GNPA — 72% evidence | 4.9/20 P/BV 0.19× · P/BV÷ROE 0.56 70% evidence | 7.2/20 RS sector -4.4% · RS bench -7.2% · 1Y -23.2%0 of 11 weeks ahead 70% evidence |
| Exact sum: 20.2 + 5.8 + 4.9 + 7.2 = 38.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Kiran Vyapar Ltdthis pageKIRANVYPAR | 33.0/100Adverse evidence64% evidence | FADING | 10.2/35 Income 0.9% · PAT -80% 62% evidence | 7.5/25 ROA 1.1% · ROE 0.1% · GNPA — 68% evidence | 3.4/20 P/BV 0.25× · P/BV÷ROE 5 100% evidence | 11.9/20 RS sector — · RS bench 4% · 1Y —5 of 9 weeks ahead 25% evidence |
| Exact sum: 10.2 + 7.5 + 3.4 + 11.9 = 33 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Systematix Corporate Services LtdSYSTMTXC | 30.1/100Adverse evidence74% evidence | TURNING | 9.8/35 Income 14.4% · PAT -80% 81% evidence | 12.5/25 ROA 3.2% · ROE 4.6% · GNPA — 68% evidence | 4.1/20 P/BV 3.37× · P/BV÷ROE 0.73 70% evidence | 3.7/20 RS sector -36.9% · RS bench -13.2% · 1Y -36.3%3 of 11 weeks ahead 70% evidence |
| Exact sum: 9.8 + 12.5 + 4.1 + 3.7 = 30.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Spice Lounge Food Works LtdSPICELOUNG | 46.1/100Thin evidence · provisional44% evidence | 20.2/35 Income 20.9% · PAT 100% 22% evidence | 12.4/25 ROA — · ROE 8.4% · GNPA — 34% evidence | 3.5/20 P/BV 15.85× · P/BV÷ROE 1.9 70% evidence | 10.0/20 RS sector 2.8% · RS bench -20.9% · 1Y -30.3%2 of 12 weeks ahead to 2026-08-23 70% evidence | |
| Exact sum: 20.2 + 12.4 + 3.5 + 10 = 46.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Ebix LtdEBIX | 45.4/100Thin evidence · provisional23% evidence | 20.4/35 Income 64.6% · PAT -45.7% 19% evidence | 11.7/25 ROA — · ROE — · GNPA — 8% evidence | 10.0/20 P/BV — · P/BV÷ROE — 0% evidence | 3.3/20 RS sector -32.6% · RS bench -38.1% · 1Y -58.5%8 of 12 weeks ahead 70% evidence | |
| Exact sum: 20.4 + 11.7 + 10 + 3.3 = 45.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24Fedders Holding Ltd511628 | 42.0/100Thin evidence · provisional47% evidence | 17.3/35 Income -29.8% · PAT 72.1% 35% evidence | 12.4/25 ROA — · ROE 7% · GNPA — 26% evidence | 8.4/20 P/BV 1.14× · P/BV÷ROE 0.16 70% evidence | 3.9/20 RS sector -13.1% · RS bench -21.5% · 1Y -37.1%0 of 12 weeks ahead to 2026-04-19 70% evidence | |
| Exact sum: 17.3 + 12.4 + 8.4 + 3.9 = 42 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. Financial companies use P/BV÷ROE and asset quality; PEG, industrial OPM and ROCE are excluded. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Kiran Vyapar Ltd's share price today?
Kiran Vyapar Ltd trades at ₹198. The company is valued at ₹549 Cr. The stock sits at 78% of its 52-week range of ₹163–₹208, +0.7% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 5 weeks in. — as of 25 September 2026.
What were Kiran Vyapar Ltd's latest quarterly results?
Kiran Vyapar Ltd reported total income of ₹33.0 Cr and net profit of ₹19.0 Cr for the Jun 26 quarter. Income rose 22.2% and profit rose 0.0% year on year. Earnings per share were ₹7.19. The net margin was 57.6%, 12.8 pp lower than a year earlier. — as of 25 September 2026.
What is Kiran Vyapar Ltd's revenue?
Kiran Vyapar Ltd reported revenue of ₹33.0 Cr in the Jun 26 quarter, +22.2% year on year. For the full FY26 fiscal year, revenue was ₹107 Cr (−5.3%). Over the last 10 years revenue compounded at 3.5% a year. — as of 25 September 2026.
What is Kiran Vyapar Ltd's profit?
Kiran Vyapar Ltd earned ₹19.0 Cr of net profit in the Jun 26 quarter, +0.0% year on year. Full-year FY26 profit was ₹1.0 Cr. The net margin ran 57.6% in the latest quarter. — as of 25 September 2026.
What is Kiran Vyapar Ltd's market cap?
Kiran Vyapar Ltd's market capitalisation is ₹549 Cr at a share price of ₹198. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 25 September 2026.
What is Kiran Vyapar Ltd's P/BV ratio?
Kiran Vyapar Ltd trades at a P/BV of 0.3×, at the 32nd percentile of its own 10-year range, against a long-run median of 0.3×. This is a comparison with the stock's own history, not a value call — as of 25 September 2026.
Does Kiran Vyapar Ltd pay a dividend?
Yes — Kiran Vyapar Ltd's dividend payout was 265% of profit in FY26, and it recorded a payout in 11 of its last 12 reported fiscal years. One of those years shows a negative ratio because profit itself was negative. This page holds the payout ratio, not a per-share amount. — as of 25 September 2026.
Is Kiran Vyapar Ltd overvalued?
On its own history, Kiran Vyapar Ltd looks cheap: its P/BV of 0.3× has been cheaper only 32% of the time in 10 years (long-run median 0.3×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 25 September 2026.
Is Kiran Vyapar Ltd growing?
The picture is mixed for Kiran Vyapar Ltd: latest-quarter revenue +22.2% year on year, profit +0.0%, and the net margin −12.8 pp at 57.6%. The 10-year compound rates are 3.5% (revenue) and −30.7% (profit). The earnings engine currently reads: mixed — as of 25 September 2026.
How is Kiran Vyapar Ltd performing?
Kiran Vyapar Ltd is in a confirmed uptrend, 5 weeks in. Its latest quarter's income rose 22.2% and profit rose 0.0% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 5 weeks. This describes what the data did, not a rating. — as of 25 September 2026.
What stage is Kiran Vyapar Ltd in?
Turning around — profit growth swung from −100.0% at the trough to +0.0% off a 2-quarter-old trough (single-quarter readings), ROE slipping at 0.0%. The read comes from the last 12 quarters of growth (revenue growth +22.2% latest, profit growth +0.0% latest) plus the ROE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 25 September 2026.
Is Kiran Vyapar Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 5 of stage 2), trading +0.7% versus its 200-day average and at 78% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 25 September 2026.
Is Kiran Vyapar Ltd beating the market?
On recent form, yes — Kiran Vyapar Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 5 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 5 months the stock moved +2% against the NIFTY 500's −2% — ahead of the index over the full window. — as of 25 September 2026.
Will Kiran Vyapar Ltd's share price go up?
This page publishes no price forecast for Kiran Vyapar Ltd. What it measures instead: the share price is ₹198, the price is in a confirmed uptrend 5 weeks in. Its P/BV of 0.3× sits at the 32nd percentile of its own 10-year range. — as of 25 September 2026.
Who owns Kiran Vyapar Ltd?
Promoters hold 75.0% of Kiran Vyapar Ltd, foreign institutions null%, domestic institutions null% and the public 25.1% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 25 September 2026.
Where is Kiran Vyapar Ltd in its business cycle?
Kiran Vyapar Ltd's FY26 net margin was 0.9%, against a 12-year band of −13.3%–89.3%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 57.6%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 25 September 2026.
What could break the Kiran Vyapar Ltd story?
Biggest watch item: the price is already 5 weeks into its uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 25 September 2026.
Is Kiran Vyapar Ltd a stock worth studying right now?
This is not investment advice. The machine read: Kiran Vyapar Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 25 September 2026.
Not SEBI Registered !! Not Investment advice !!